Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review ; volume:8 ; number:1 ; day:29 ; month:8 ; year:2018 ; pages:1-11 ; date:12.2018
EJNMMI Research ; 8, Heft 1 (29.8.2018), 1-11, 12.2018
- Creator
-
Huizing, Daphne Merel Valerie
- Contributor
-
de Wit-van der Veen, Berlinda Jantina
Verheij, Marcel
Stokkel, Marcellus Petrus Maria
SpringerLink (Online service)
- DOI
-
10.1186/s13550-018-0443-z
- URN
-
urn:nbn:de:101:1-2018102510571541746204
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Huizing, Daphne Merel Valerie
- de Wit-van der Veen, Berlinda Jantina
- Verheij, Marcel
- Stokkel, Marcellus Petrus Maria
- SpringerLink (Online service)
Other Objects (12)
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice